Jitai Technology and Eli Lilly Partner on Tissue-Specific LNP Delivery in Deal Worth Up to $1.1B

The significance here is validation of AI-driven delivery design by a major pharma counterparty, not the headline number: the up-to-$1.1B framing is contingent, and the material discloses no split between upfront, milestones or research funding. It matters most for the small-cap AI-biotech cohort, where platform credibility is often set by who signs, not what is booked. The open question is whether tissue-specific LNP targeting becomes a repeatable licensing category or remains a one-off validation event for Jitai.